Fahid Naseer

Fahid Naseer is a Senior Analyst at Outcome Capital who draws from a unique combination of M&A, strategic advisory, and scientific experiences. Before business school, Fahid has a breadth of experience in business and corporate development as well as life science commercial strategy consulting.

Prior to Outcome Capital, Fahid was an analyst at Jupiter Life Science Consulting assisting in drug product launch, pricing, and market access commercial strategy development. Prior to Jupiter, Fahid was in the corporate development group at Merrimack Pharmaceuticals where he assessed potential drug targets, M&A opportunities, and strategic finance initiatives. Fahid began his career with the business development team at Parexel International where he was responsible for customer strategy, and subsequently transitioned to Vertex where he focused on cystic fibrosis drug launches in Europe. After his time in life sciences business and corporate development, Fahid entered the investment banking industry as a Senior Analyst in Progress Partners’ technology group, before transitioning to Outcome to focus exclusively on life sciences and healthcare transactions. Fahid has extensive experience as a life sciences researcher conducting oncology research a Massachusetts General Hospital as well as computational chemistry research at New Jersey Medical School.

Fahid received a B.S. in biochemistry from the University of Massachusetts, Boston, a M.S. in biomedical science from Rutgers New Jersey Medical School, and an MBA from Babson College. In addition to his formal coursework, Fahid has also completed valuation and financial modeling seminars with leading financial services providers.